OCU410ST
Study Overview
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.
This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
Study title
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for STARGARDT DISEASE
Medical Condition(s)
Stargardt Disease
Product
AAV-hRORA
OCUGEN PROTOCOL NUMBER
OCU410ST-101
NUMBER OF SUBJECTS
Up to 42 adults who meet eligibility criteria
STUDY LENGTH
12 months
SEX
Male & Female
STUDY DATES
August 2023 – December 2025
AGE
18+
PHASE
1/2
COUNTRY
United States